ORG Partners LLC Grows Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

ORG Partners LLC increased its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3,411.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 316 shares of the medical equipment provider’s stock after buying an additional 307 shares during the quarter. ORG Partners LLC’s holdings in Intuitive Surgical were worth $138,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of Intuitive Surgical during the fourth quarter worth about $1,313,238,000. Capital Research Global Investors purchased a new stake in Intuitive Surgical in the 1st quarter worth approximately $374,390,000. Assenagon Asset Management S.A. grew its position in shares of Intuitive Surgical by 111.7% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,285,565 shares of the medical equipment provider’s stock worth $513,056,000 after buying an additional 678,375 shares during the last quarter. Coatue Management LLC increased its stake in shares of Intuitive Surgical by 65.7% during the fourth quarter. Coatue Management LLC now owns 1,301,595 shares of the medical equipment provider’s stock valued at $439,106,000 after buying an additional 516,054 shares during the period. Finally, Vanguard Group Inc. raised its holdings in shares of Intuitive Surgical by 1.6% during the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock valued at $12,319,358,000 after acquiring an additional 493,126 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Intuitive Surgical

In other news, EVP Robert Desantis sold 584 shares of the firm’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $404.41, for a total value of $236,175.44. Following the transaction, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,226,681.46. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other Intuitive Surgical news, EVP Myriam Curet sold 2,818 shares of the stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total value of $1,291,010.34. Following the transaction, the executive vice president now directly owns 298 shares in the company, valued at $136,522.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Robert Desantis sold 584 shares of the business’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $404.41, for a total transaction of $236,175.44. Following the sale, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at approximately $2,226,681.46. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,372 shares of company stock worth $6,667,430. Insiders own 0.90% of the company’s stock.

Intuitive Surgical Price Performance

Shares of Intuitive Surgical stock traded up $4.97 during trading on Thursday, hitting $476.18. 349,105 shares of the company’s stock traded hands, compared to its average volume of 1,550,413. Intuitive Surgical, Inc. has a 1 year low of $254.85 and a 1 year high of $478.10. The business has a 50-day simple moving average of $440.74 and a 200-day simple moving average of $406.25. The stock has a market capitalization of $168.90 billion, a P/E ratio of 85.06, a PEG ratio of 4.97 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. The firm had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The business’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.18 earnings per share. On average, equities analysts predict that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on ISRG. The Goldman Sachs Group started coverage on shares of Intuitive Surgical in a report on Thursday, May 30th. They issued a “buy” rating and a $500.00 price target on the stock. JPMorgan Chase & Co. boosted their price target on shares of Intuitive Surgical from $475.00 to $495.00 and gave the company an “overweight” rating in a research report on Friday, July 19th. Stifel Nicolaus raised their price objective on shares of Intuitive Surgical from $430.00 to $475.00 and gave the stock a “buy” rating in a report on Friday, July 19th. Piper Sandler upped their target price on Intuitive Surgical from $490.00 to $495.00 and gave the stock an “overweight” rating in a report on Friday, July 19th. Finally, Jefferies Financial Group raised their target price on Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a research note on Friday, April 19th. Six investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $442.30.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.